2018년 10월 31일 11:35

Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA®▼ (D/C/F/TAF) in Treatment-Naïve Adults with HIV-1

The Janssen Pharmaceutical Companies of Johnson & Johnson today unveiled 96-week results from the pivotal Phase 3 AMBER study of SYMTUZA® (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (D/C/F/TAF)) at HI...

건강제약연구개발

2018년 5월 23일 19:20

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).[1] ViiV He...

건강제약연구개발

2018년 3월 26일 11:30

Janssen Announces Positive CHMP Opinion for JULUCA™▼ (dolutegravir/rilpivirine)

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for ...

건강제약연구개발

2017년 10월 26일 09:15

Janssen’s New Darunavir-Based Single Tablet Regimen SYMTUZA® Shows Positive Outcome in Treatment of Antiretroviral-Naïve HIV Patients

Janssen’s new once-daily, single tablet combination therapy SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]) has shown to be both highly effective and well-tolerated in treating antiretroviral-naïve HIV-1 patients th...

건강제약연구개발

2017년 7월 28일 09:40

Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV

Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for SYMTUZA™ (darunav...

건강제약연구개발

2017년 7월 28일 09:40

얀센 ‘심투자’, CHMP ‘긍정 의견’ 받아… HIV 치료를 위한 최초의 다루나비르 기반 단일복합정

얀센-실락 인터내셔널(Janssen-Clog International NV, 이하 얀센)이 유럽의약품청(European Medicines Agency, 약칭 EMA) 산하 약물사용자문위원회(Committee for Medicinal Products for Human Use, 약칭 CHMP)가 ‘심투자’(SYMTUZA™: 다루나비르(darunavir)/코비시...

건강제약연구개발

2017년 7월 26일 13:50

Janssen Announces Phase 3 Pivotal Study Results for Darunavir-Based Complete Treatment Regimen

Janssen-Cilag International NV (Janssen) today announced that an investigational single-tablet regimen (STR) containing darunavir is effective and well tolerated. Results from the pivotal Phase 3 EMERALD study showed that a once-daily STR containi...

건강제약연구개발

2017년 7월 24일 18:10

Data Published in The Lancet Shows High Efficacy at 96 Weeks for First Investigational Two-Drug, Long-Acting Injectable HIV Regimen

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced that a regimen of two investigational long-acting, injectable formulations of HIV medicines —Janssen’s rilpivirine and ViiV Hea...

건강제약연구개발

2017년 6월 15일 11:15

Pimodivir Alone or in Combination with Oseltamivir Demonstrated a Significant Reduction in Viral Load in Adults with Influenza A

Janssen Pharmaceuticals, Inc. (Janssen) today announced results from the Phase 2b Topaz Trial which demonstrated that treatment with pimodivir (JNJ-63623872) significantly decreased viral load over seven days versus placebo, in adult patients with...

건강제약연구개발